Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator

Table 1 Baseline demographic and lung functions on initial spirometry

Variables	Salbutamol group (n = 209)				Fluticasone/Salmeterol group (n = 206)				¹P-value
Variables	Normal	overweight	Obese	P-value	Normal	overweight	obese	P-value
Number of participants (%)	70 (33.49)	69 (33.01)	70 (33.49)		68 (33.01)	68 (33.01)	70 (33.98)
Age (years)	37.93 ± 12.4	38.49 ± 14.5	42.95 ± 13.8	0.059	39.14 ± 8.1	41.85 ± 9.3	45.14 ± 11.9	0.036	NS
Gender (M/F)	46/24	33/36	26/44	0.094	33/35	38/30	31/39	0.174	NS
BMI (kg/m²)	22.96 ± 2.21	27.81 ± 1.37	35.67 ± 4.58	< 0.001*	23.2 ± 5.83	28.06 ± 1.8	35.2 ± 6.3	< 0.001*	NS
FEV₁ (L)	3.15 ± 1.2	2.93 ± 0.81	2.79 ± 1.03	0.115	3.72 ± 1.46	3.29 ± 1.28	3.24 ± 1.17	0.064	NS
FEV₁% of predicted	76.2 ± 12.6	74.5 ± 16.4	72.41 ± 18.3	0.372	78.28 ± 12.5	77.05 ± 11.3	76.56 ± 12.9	0.699	NS
FVC (L)	3.45 ± 1.14	3.41 ± 0.78	3.34 ± 0.97	0.796	4.16 ± 1.41	3.92 ± 1.36	3.64 ± 1.27	0.079	NS
FVC% of predicted	89.78 ± 10.8	87.15 ± 12.37	86.63 ± 14.52	0.281	90.18 ± 12.8	87.22 ± 10.41	85.34 ± 13.62	0.068	NS
FEV₁/FVC	73.88 ± 17.61	73.15 ± 19.28	70.94 ± 18.13	0.615	76.83 ± 15.8	74.52 ± 14.7	71.24 ± 16.51	0.112	NS

M/F: male/Female; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity
¹The p-value difference between the salbutamol and Fluticasone/salmeterol groups
*Statistically significant differences within groups

ISSN: 1471-2466